car19 t cells carrying cytoplasmic activated pd-1
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2018 (NCT03540303)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03540303 | Phase 1 | Apr 12, 2018 | Henan Medical University, The Beijing Pregene Science and Technology Company, Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| The Beijing Pregene Science and Technology Company, Ltd. | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1